相似文献
1
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study.致编辑的信：提高胆管癌研究的严谨性和影响力：解决PTPN9-FGFR2相互作用研究中的关键问题。
Hepatology. 2024 Sep 1;80(3):E44-E45. doi: 10.1097/HEP.0000000000000932. Epub 2024 Jun 24.
2
PTPN9 dephosphorylates FGFR2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.PTPN9 通过与 ACAP1 相互作用使 FGFR2 pY656/657 去磷酸化，从而改善胆管癌患者对 pemigatinib 的疗效。
Hepatology. 2024 Apr 1;79(4):798-812. doi: 10.1097/HEP.0000000000000552. Epub 2023 Jul 27.
3
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.肝内胆管癌中的成纤维细胞生长因子受体 2 易位。
Hum Pathol. 2014 Aug;45(8):1630-8. doi: 10.1016/j.humpath.2014.03.014. Epub 2014 Apr 13.
4
Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.成纤维细胞生长因子受体 2（FGFR2）在肝细胞癌-胆管细胞癌联合癌和肝内胆管癌中的表达：临床病理研究。
Virchows Arch. 2024 Jun;484(6):915-923. doi: 10.1007/s00428-024-03792-x. Epub 2024 Mar 27.
5
Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.FGFR2 易位导致肝内胆管癌的功能异常。
Cytokine Growth Factor Rev. 2020 Apr;52:56-67. doi: 10.1016/j.cytogfr.2019.12.005. Epub 2019 Dec 19.
6
Gatekeeper Mutations and Intratumoral Heterogeneity in -Translocated Cholangiocarcinoma.跨膜胆汁腺癌中的守门员突变和肿瘤内异质性。
Cancer Discov. 2017 Mar;7(3):248-249. doi: 10.1158/2159-8290.CD-17-0057.
7
Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.成纤维细胞生长因子受体 2（FGFR2）融合在日本肝内胆管癌患者中的研究。
Jpn J Clin Oncol. 2021 May 28;51(6):911-917. doi: 10.1093/jjco/hyab029.
8
[New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement].[欧洲新批准药物：培米替尼 - 用于治疗伴有FGFR2融合或重排的胆管癌]
Bull Cancer. 2021 May;108(5):446-447. doi: 10.1016/j.bulcan.2021.03.007. Epub 2021 Apr 27.
9
Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.针对胆管癌中 FGFR2 融合的联合疗法。
Trends Cancer. 2022 Feb;8(2):83-86. doi: 10.1016/j.trecan.2021.11.001. Epub 2021 Nov 25.
10
Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.英菲格拉替尼用于经治的伴有FGFR2融合或重排的胆管癌
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):773-775. doi: 10.1016/S2468-1253(21)00220-X. Epub 2021 Aug 3.
Zotero 插件